Company: CDT
Filing Date: 2025-04-16
Form Type: 8-K
Source: 0001641172-25-005036
Chunk: 1

Company: CDT Equity Inc.
Filing Date: 2025-04-16
Form: 8-K
Item: Item 5.02
Chunk 1
---
 explorer and entrepreneur. He has served as a member of the Board since September 2023. He was
a co-founder of Conduit Pharmaceuticals Limited (“ Old Conduit”) and has served as a board member of Old Conduit since 2019.
Dr. Regan also founded Corvus Capital Limited (“ Corvus Capital”) and has been its Chief Executive Officer since 2008. Corvus
Capital is an investment vehicle that was previously listed on the London Stock Exchange prior to being taken private in 2008. Corvus
Capital continues to invest in a number of industries and sectors. Dr. Regan also has experience as an investor in a number of public
and private companies, including ASOS. com Ltd, a global online fashion and beauty retailer, Virtual Internet, an IT services company
that specializes in hosting infrastructure such as VMWare cloud hosting and Managed and Dedicated Servers, and Imperial Energy Corporation
plc, an upstream oil and gas exploration and production company. Prior to that, Dr. Regan was the Chief Executive Officer of Hobson Plc,
which was listed on the London Stock Exchange, until its sale in 1996 through a cash takeover. Dr. Regan has a strong interest in the
use of bio-inspired science to create solutions for present day problems. In 2014, he was awarded a PhD from Oxford Brookes University
for his research in writing and developing a bio-inspired algorithm for forecasting the financial markets. He is passionate about the
polar regions and is an accomplished polar explorer having led a number of expeditions to both the Arctic and Antarctica. Dr. Regan was
selected to serve on the Board following the business combination based on his knowledge of Old Conduit and his extensive experience
in investing, financing, overseeing and developing companies.

Dr.
Regan sits on the board of directors of Sarborg Limited (“ Sarborg”), a significant stockholder of the Company, with which
the Company, as previously disclosed, has entered into a Services Agreement (the “ Sarborg Agreement”) with in December 2024.
Since the beginning of this fiscal year, as previously disclosed in a Current Report to Form 8-K filed on April 4, 2025, on March 31,
2025, the Company entered into an additional license and use agreement with Sarborg (the “ Additional Agreement”) covering
certain additional deliverables and incorporating a new scope of work focused on analysis of Conduit’s acquired AstraZeneca assets.
Dr. Regan